Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25323241 | 1.00 | GPR119 (0.45) | GPR119ARALDH1A1EGLN2NR1H2 | |
| SCHEMBL25320296 | 0.87 | NR1H2 (0.38) | GPR119ARNR1H2KDM4D | |
| SCHEMBL30550969 | 0.87 | NR1H2 (0.38) | GPR119ARNR1H2KDM4D | |
| SCHEMBL25320301 | 0.87 | NR1H2 (0.38) | GPR119ARNR1H2KDM4D | |
| SCHEMBL25322423 | 0.85 | GPR119 (0.41) | GPR119NR1H2 | |
| SCHEMBL25322429 | 0.85 | GPR119 (0.41) | GPR119NR1H2 | |
| SCHEMBL24364304 | 0.85 | ESR2 (0.36) | GPR119ALDH1A1 | |
| SCHEMBL24367169 | 0.84 | MEN1 (0.41) | — | |
| SCHEMBL24363976 | 0.84 | HDAC2 (0.41) | — | |
| SCHEMBL25320417 | 0.82 | GPR119 (0.42) | GPR119KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | GPR119 1037/4885AR 129/4885ALDH1A1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.